Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Sporadic Inclusion Body Myositis Clinical Trial

Official title:
A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BYM338 in Patients With Sporadic Inclusion Body Myositis

Status Completed

Clinical Trial Summary

This study will assess the efficacy, safety and tolerability of BYM338 in patients with sporadic Inclusion Body Myositis

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01423110
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 2
Start date	August 2011
Completion date	May 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01925209` - Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients	Phase 2/Phase 3
Active, not recruiting	`NCT05046821` - Sporadic Inclusion Body Myositis Natural History Study
Completed	`NCT02573467` - An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203	Phase 3
Not yet recruiting	`NCT02735447` - Evidence Generation for Improving Life of People With sIBM: The ENGAGE Study	N/A
Completed	`NCT02317094` - Blood-flow Restricted Exercise in Inclusion Body Myositis	N/A
Completed	`NCT01519349` - Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis	Phase 1
Withdrawn	`NCT03710941` - Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis	Phase 2
Completed	`NCT04421677` - Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis	Phase 1